The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion
Authors:
- 16 December 2011
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (5) , 771-779
Abstract
In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited. BL22 is a recombinant protein composed of the variable region of a monoclonal antibody that binds to CD22 and of PE38, a truncated Pseudomonas exotoxin. BL22 is a very potent drug already used in patients with hairy cell leukemia, whereas in chronic lymphocytic leukemia its cytotoxicity is limited by a lower expression of CD22. Here we demonstrate that this limitation can be overcome by pre-activation of chronic lymphocytic leukemia cells with bryostatin 1. Primary malignant B cells from chronic lymphocytic leukemia and mantle cell lymphoma patients were used in vitro to assess the therapeutic impact of drug combinations using BL22 and bryostatin 1. We demonstrate that bryostatin 1 sensitizes chronic lymphocytic leukemia cells for the cytotoxic effects of BL22 through activation of protein kinase C and subsequently increased CD22 surface expression. Dose and time response analysis reveals that activation of protein kinase C further activates an autocrine feedback loop degrading protein kinase C-βII protein. Depletion of protein kinase C-βII and upregulation of CD22 persist for several days following pre-stimulation with bryostatin 1. Therefore, our data provide a rationale for the sequential administration of BL22 following bryostatin 1 treatment. In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis. Our data suggest that the combination of bryostatin 1 with antibodies directed against CD22 is a potent drug combination for the treatment of low- and high-grade B-cell lymphoma.Keywords
This publication has 41 references indexed in Scilit:
- Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2003
- Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβBioorganic & Medicinal Chemistry Letters, 2003
- CD22 as a target of passive immunotherapySeminars in Oncology, 2003
- Protein Kinase C Regulates FADD Recruitment and Death-inducing Signaling Complex Formation in Fas/CD95-induced ApoptosisJournal of Biological Chemistry, 2001
- Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell LeukemiaNew England Journal of Medicine, 2001
- Rituximab Dose-Escalation Trial in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Activation-dependent degradation of protein kinase CηOncogene, 2000
- Chemistry and clinical biology of the bryostatinsBioorganic & Medicinal Chemistry, 2000
- Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.2000
- Establishment and characterization of a mantle cell lymphoma cell lineBritish Journal of Haematology, 1998